Cephalon (CEPH) Tops Q2 View; Guides Q3
More News related to CEPH
- Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
- Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
- Piper Jaffray Initiates Coverage on Cephalon (CEPH) with a Buy
- Goldman Sachs Initiates Coverage on Several Pharmaceutical Companies - CEPH, ENDP, FRX, KG, SEPR & WCRX
- Soleil Securities Initiates Coverage on Cephalon (CEPH) with a Buy
More News related to Earnings
- Deutsche Bank Downgrades and Lowers Estimates On Global Metals and Mining Companies (RIO, AAUK)
- Soleil Securities Maintains a Buy on Airgas (ARG), Lowers Estimates and Price Target
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
Cephalon, Inc. (Nasdaq: CEPH) reports Q2 EPS of $1.25, versus the analyst estimate of $1.07. Revenues for the quarter were $485 million, versus the consensus of $469.79 million.
Sees Q3 EPS of $1.25-$1.35, versus the consensus of $1.22 and revs of $480-$490 million, versus $481.6 million.
Related Categories
EarningsGuidance
Stocks Mentioned
-1.60Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
